Date | Price Target | Rating | Analyst |
---|---|---|---|
9/14/2022 | $12.00 | Buy | Berenberg |
2/28/2022 | $50.00 → $30.00 | Overweight | Piper Sandler |
11/10/2021 | $35.00 → $36.00 | Buy | HC Wainwright & Co. |
10/20/2021 | Outperform | Cowen | |
6/24/2021 | $35.00 | Buy | HC Wainwright & Co. |
4 - Kronos Bio, Inc. (0001741830) (Issuer)
4 - Kronos Bio, Inc. (0001741830) (Issuer)
4 - Kronos Bio, Inc. (0001741830) (Issuer)
SAN MATEO, Calif., and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced the following upcoming conferences: H.C. Wainwright 26th Annual Global Investment Conference, taking place September 9–11, 2024 in New York, NYKronos Bio President and Chief Executive Officer, Norbert Bischofberger, Ph.D., will present on Monday, September 9, at 2:30 p.m. ETAmerican Association for Cancer Research (AACR) 15th Biennial Ovarian Cancer Research Symposium, taking place September 20–21, 2024 in Seattle, WAKronos Bio Di
— First patient in platinum-resistant high-grade serous ovarian cancer cohort was dosed on optimized dose and schedule with istisociclib (KB-0742); expect data update in 1H 2025 — — KB-9558 IND-enabling studies for multiple myeloma remain on track to be completed in Q4 2024 — — Pipeline update includes an additional indication for KB-9558 in HPV-driven tumors and a separate p300 program focused on autoimmune indications — — $136.6 million cash and cash equivalents expected to fund operations into 2H 2026 — SAN MATEO, Calif. and CAMBRIDGE, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to developing small molecule therapeutics that addre
— KB-0742 cleared 80mg four-days-on, three-days-off dosing schedule in dose escalation — — Company expects to provide an efficacy update on this expansion cohort in 1H 2025 — SAN MATEO, Calif. and CAMBRIDGE, Mass., July 23, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced the first patient dosed in an expansion cohort with KB-0742 at a dose of 80mg given on a four-days-on, three-days-off schedule. This expansion cohort is enrolling platinum-resistant patients with high-grade serous ovarian cancer (HGSOC), a tumor type which is
8-K - Kronos Bio, Inc. (0001741830) (Filer)
10-Q - Kronos Bio, Inc. (0001741830) (Filer)
8-K - Kronos Bio, Inc. (0001741830) (Filer)
4 - Kronos Bio, Inc. (0001741830) (Issuer)
4 - Kronos Bio, Inc. (0001741830) (Issuer)
4 - Kronos Bio, Inc. (0001741830) (Issuer)
Berenberg initiated coverage of Kronos with a rating of Buy and set a new price target of $12.00
Piper Sandler reiterated coverage of Kronos Bio with a rating of Overweight and set a new price target of $30.00 from $50.00 previously
HC Wainwright & Co. reiterated coverage of Kronos Bio with a rating of Buy and set a new price target of $36.00 from $35.00 previously
SAN MATEO, Calif. and CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced that it has appointed Deborah Knobelman, Ph.D., as Chief Operating Officer and Chief Financial Officer effective June 3, 2024. Dr. Knobelman will oversee the finance, accounting, business development, investor relations and corporate strategy functions. "I'm excited to have Deb join our team. She is a proven life sciences leader, and her strategic vision will play a critical role in shaping the future of Kronos Bio. As we continue to
STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas
Data from the Phase 1 dose escalation portion of the Phase 1/2 KB-0742 study will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October 2023 The Company recently opened the third dosing cohort in the escalation portion of the Phase 1b/2 study of lanraplenib in combination with gilteritinib FLT3-mutated relapsed/refractory acute myeloid leukemia $219.7 million in cash, cash equivalents and investments as of June 30, 2023, providing expected cash runway into 2H 2025 SAN MATEO, Calif. and CAMBRIDGE, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to transforming the lives of those aff
SC 13D/A - Kronos Bio, Inc. (0001741830) (Subject)
SC 13D/A - Kronos Bio, Inc. (0001741830) (Subject)
SC 13D - Kronos Bio, Inc. (0001741830) (Subject)
— KB-0742 cleared 80mg four-days-on, three-days-off dosing schedule in dose escalation — — Company expects to provide an efficacy update on this expansion cohort in 1H 2025 —SAN MATEO, Calif. and CAMBRIDGE, Mass., July 23, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced the first patient dosed in an expansion cohort with KB-0742 at a dose of 80mg given on a four-days-on, three-days-off schedule. This expansion cohort is enrolling platinum-resistant patients with high-grade serous ovarian cancer (HGSOC), a tumor type which is part
Gainers Longeveron (NASDAQ:LGVN) stock increased by 74.6% to $3.16 during Thursday's regular session. The company's market cap stands at $20.0 million. BioRestorative Therapies (NASDAQ:BRTX) stock rose 27.4% to $1.72. The market value of their outstanding shares is at $11.6 million. Aethlon Medical (NASDAQ:AEMD) shares rose 26.84% to $0.66. The market value of their outstanding shares is at $3.3 million. Sharps Technology (NASDAQ:STSS) stock moved upwards by 23.58% to $0.37. The company's market cap stands at $6.5 million. Biomea Fusion (NASDAQ:BMEA) stock moved upwards by 20.95% to $5.6. The market value of their outstanding shares is at $201.2 million. iSpecimen (NASDAQ:ISPC) shares
The Dow Jones index closed lower by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Kronos Bio The Trade: Kronos Bio, Inc. (NASDAQ:KRON) President and CEO Norbert W Bischofberger bought a total of 3,005,122 shares at an average price of $1.04. To acquire these shares, it cost around $3.12 million. What's Happening: On May 21, Kro
Demonstrated on-mechanism, single agent anti-tumor activity in heavily pre-treated patients with transcriptionally addicted solid tumors Showed manageable safety profile, with no grade 3/4 neutropenia, dose proportional exposure, dose-dependent target engagement, and 24-hour plasma half-life Dose escalation continues; dosing of patients at the 80 mg dose level is ongoing Enrollment ongoing in dose expansion phase in MYC-dependent and other transcriptionally addicted solid tumors, including lung, ovarian, and triple negative breast cancers Company to host conference call and webcast today at 4:30 PM ET with key opinion leader and KB-0742 trial investigator, Miguel Villalona-Calero, M.D.
SAN MATEO, Calif., and CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will host a conference call and webcast on Friday, October 13, 2023, at 4:30 p.m. ET., followed by a Q&A session. The event will feature trial investigator, Miguel Villalona-Calero, M.D, Medical Oncologist and Director of Early Therapeutics, City of Hope, along with Kronos Bio management, who will discuss the current treatment landscape for patients with MYC-dependent solid tumors, provide an overview of KB-0742 and further discuss the poster to be presented at the AACR-NCI-EORTC Interna
Company to discontinue Phase 3 entospletinib trial for strategic reasons Enrollment continues for Phase 1/2b trial in relapsed/refractory AML with Kronos Bio's next generation SYK inhibitor, lanraplenib Company on track to provide KB-0742 update from ongoing Phase 1/2 clinical trial in Q4 With $270.3 million in cash, cash equivalents and investments as of Sept. 30, 2022, Kronos Bio extends expected cash runway from Q4 2024 into Q2 2025 Conference call and webcast scheduled for today at 4:30 p.m. ET SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to transforming the lives of those affected by cancer, today